



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K X</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 90/14069</b>  <b>(43) International Publication Date:</b> 29 November 1990 (29.11.90)
<b>(21) International Application Number:</b> PCT/US90/02884 <b>(22) International Filing Date:</b> 14 May 1990 (14.05.90)  <b>(30) Priority data:</b> 351,695 12 May 1989 (12.05.89) US  <b>(71) Applicant:</b> THE STATE OF OREGON acting by and through THE STATE BOARD OF EDUCATION on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201 (US).  <b>(72) Inventors:</b> SHIPLEY, Gary, D. ; 6230 S.W. 47th. Place, Portland, OR 97221 (US). PITTELKOW, Mark, R. ; 721 12th Avenue, S.W., Rochester, MN 55901 (US). COOK, Paul, W. ; 10919 N.W. 29th. Avenue, Vancouver, WA 98685 (US).		<b>(74) Agents:</b> MURASHIGE, Kate, H. et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> KERATINOCYTE AUTOCRINE FACTOR  <b>(57) Abstract</b>  Keratinocyte autocrine factor (KAF) can be isolated from human keratinocytes and is an effective and selective mitogen for keratinocytes in comparison to fibroblasts. Methods of purifying KAF using sulfated glycosaminoglycans, methods to inhibit the effect of KAF using sulfated glycosaminoglycans, and methods to assay for stimulators and inhibitors of KAF activity and production are described.		

## DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

-1-

5

KERATINOCYTE AUTOCRINE FACTORTechnical Field

10           The invention relates to growth factors which are mitogenic in epidermal cells. More specifically, the invention concerns an autocrine growth factor secreted by keratinocytes capable of ameliorating pathological conditions such as skin lesions.

15

Background Art

          Keratinocytes are the major cell type in the epidermis, a multilayered group of cells without blood vessels on the surface of the skin. Presumably,  
20 proliferation and growth of epidermal cells in vivo is nourished by nutrients from the dermal layer, including growth factors. Keratinocytes have been propagated in vitro in continuous culture using defined medium for example as described in Shipley, G.D., et al., Arch Dermatol (1987) 123:1541A-1544A. The medium contains  
25 various inorganic ions, trace elements, amino acids, vitamins and other organic compounds and is not qualitatively different from defined media used to culture other mammalian cell lines. In this publication it was  
30 noted that insulin and epidermal growth factor (EGF) were required for clonal growth in vitro and that hydrocortisone was beneficial.

          Basic fibroblast growth factor (bFGF) is able to replace EGF in supporting the clonal growth of  
35 keratinocytes in a dose-dependent manner; acidic fibroblast growth factor (aFGF) is also a potent mitogen

SUBSTITUTE SHEET

-2-

(Shipley, G.D., et al., J Cell Physiol (1989) 138:511-518, incorporated herein by reference). These FGFs are members of a class of heparin-binding growth factors (HBGF) which includes the products of several potential oncogenes. The ability of bFGF to stimulate proliferation of keratinocytes is inhibited by heparin; heparin has no effect on stimulation by EGF or TGF $\alpha$  and only minimal effect on stimulation by aFGF.

It is also known that transforming growth factors (TGF) are produced by virally transformed cells and tumor cell lines. These factors stimulate soft agar colony formation of cells that are normally anchorage-dependent and cause the overgrowth of these cells in a monolayer culture. Two major classes of transforming growth factors have been identified--TGF- $\alpha$  and TGF- $\beta$ . Other growth factors including platelet-derived growth factor (PDGF) and HBGFs also can contribute to anchorage-independent growth of some target cells. Shipley, G.D., J Tissue Culture Methods (1986) 10:117-123, describes a simple in vitro serum-free thymidine-incorporation assay for detection of transforming growth factors.

A purified factor from fibroblasts designated keratinocyte growth factor (KGF) was described by Rubin, J.S., et al., Proc Natl Acad Sci USA (1989) 86:802-806. This factor is labile to acid treatment and stable to reduction. Other growth factors which have been described are transforming growth factor type- $\beta$  (Halper et al., Cancer Res (1987) 47:4552-4559), and DNA synthesis factor (Masuda et al., In Vitro Cell and Devel Biol (1988) 24:893-899; Masuda et al., Cell Biol Int Rep (1987) 11:359-365).

Shoyab, M., et al., Proc Natl Acad Sci USA (1988) 85:2528-2532, described a glycoprotein which they termed amphiregulin (AR) which inhibits the growth of human carcinoma cells in culture but stimulates

-3-

proliferation of human fibroblasts and other tumor cells. Amphiregulin was obtained from serum-free conditioned medium of the MCF-7 cell line derived from a human breast carcinoma which was stimulated with phorbol 12-myristate 13-acetate. Unlike keratinocyte growth factor (KGF), AR was not acid labile and the foregoing report indicated that the glycosylation could be removed but activity retained, and the N-terminal sequence was disclosed. In a subsequent paper, Shoyab, M., et al., Science (1989) 243:1074-1076, the complete amino acid sequence of a "truncated" form containing 78 amino acids as determined using protein-sequencing techniques as well as a larger form containing 6 additional amino acid sequences at the N-terminal end was reported. It was further disclosed that amphiregulin binds to the EGF receptor but less strongly than does EGF itself. Amphiregulin was shown to stimulate the growth of the murine keratinocyte cell line Balb/MK and could supplant the EGF requirement in these cells. In these assays, the keratinocytes were plated at  $10^4$  cells per well and cultured overnight to a starting cell density of approximately  $10^4$  cells/cm<sup>2</sup>.

In a more recent publication, Plowman, G.D., et al., Mol Cell Biol (1990) 10:1969-1981, this same group reported the cloning of the gene encoding the 252 amino acid precursor of the 84 amino acid amphiregulin "mature" peptide secreted by MCF-7 cells, which precursor had an organization similar to the transmembrane precursor corresponding to TGF- $\alpha$ . Human placenta and ovaries also were reported to express significant amounts of the AR transcript. Assessment of the biological activity of the amphiregulin was not elaborated over that of the Science paper which had shown only data that AR had stimulatory activity with respect to murine keratinocytes under the high cell density conditions of the reported assay. These cells do not make KAF.

**SUBSTITUTE SHEET**

-4-

The reported amino acid sequence of amphiregulin matches that of the keratinocyte autocrine factor of the present invention. These data are also the subject of published British application GB2214185A, published

5 31 August 1989.

Two types of models have been described to account for the loss of growth control in tumor cells. In one, the "autocrine hypothesis," the production of and response to a growth factor by the same cells, leading to  
10 an increase in proliferation rate of these cells, is postulated. In an alternative "paracrine hypothesis," secretion of factors by the tumor cells are thought to stimulate the production of growth factors by surrounding tissues, which, in turn, stimulate the growth of the tumor  
15 cells.

In short, while the process whereby cells are permitted to proliferate in vivo and in vitro is far from understood, it is known that there is a complex inter-relationship of growth factors, which in some way  
20 regulates this proliferation. The present invention relates to an autocrine factor selective for the proliferation of keratinocytes.

#### Disclosure of the Invention

25 It has been found that keratinocytes, when plated at higher than  $10^3$  cells/cm<sup>2</sup>, can be grown without supplementation with polypeptide growth factors, thus suggesting the autocrine stimulation of proliferation by self-secreted growth factors (Shipley, G.D., et al., J Cell Physiol (1989) 138:511-518 (supra), incorporated  
30 herein by reference). One of these growth factors, designated keratinocyte autocrine factor herein (KAF), binds to heparin and can be purified by heparin affinity chromatography.

35 Thus, in one aspect, the invention relates to methods to purify keratinocyte autocrine factor which

**SUBSTITUTE SHEET**

-5-

comprise contacting a sample containing the KAF to be purified with a suitable sulfated glycosaminoglycan (GAG) or carbohydrate immobilized to a solid support under conditions wherein the KAF is adsorbed. The adsorbed KAF  
5 is then eluted from the solid support, preferably in an elution protocol wherein a number of fractions are obtained, only some of which contain KAF.

In another aspect, the invention is directed to a method to inhibit the mitogenic effect of KAF on  
10 responsive cells either in vivo or in vitro by taking advantage of the inhibitory effect of certain sulfated glycosaminoglycans and carbohydrates on KAF. For in vitro inhibition, the sulfated GAG or other sugar may be added directly to the cell culture; for in vivo inhibition, the  
15 inhibitor is administered to the subject to minimize the mitogenic effect of endogenous KAF.

The invention also relates to methods to identify stimulators and inhibitors of KAF activity and KAF production. To assess regulation of KAF activity,  
20 candidate substances are added to KAF-treated cultures of cells responsive to KAF, such as AKR-2B cells in serum-free medium and their effect on indices of growth, such as labeled thymidine incorporation, is measured. This assay is conducted in the presence and absence of heparin or  
25 other sulfated carbohydrate inhibitor to isolate the response due to KAF. For stimulators and inhibitors of KAF production, candidate substances are added to culture media for KAF-producing cells and their effect on KAF mRNA and/or protein is measured.

30 In still other aspects, the invention is directed to a method to produce KAF by culturing human keratinocytes or mammary epithelial cells under conditions which favor KAF production and recovering the KAF produced, preferably by heparin affinity chromatography.

35 In still other aspects, the invention is directed to the use of KAF to minimize scarring in surface

**SUBSTITUTE SHEET**

-6-

wounds by taking advantage of the selective mitogenic effect of KAF on keratinocytes in comparison to fibroblasts. In still another aspect, the invention relates to methods to grow keratinocytes from low density  
5 in culture by enhancing their growth with KAF, and to drug delivery systems which depend on slow release of KAF from sulfated carbohydrates.

The invention also relates to keratinocyte autocrine factor itself in purified and isolated form, to  
10 recombinant materials and methods for its production, and to antibodies immunoreactive with this protein or glycoprotein.

#### Brief Description of the Drawings

15 Figure 1 shows the effect of heparin on the activity of TGF-alpha and of conditioned medium from human keratinocytes on AKR-2B cells.

Figure 2 shows the effect of heparin on the mitogenic ability of a number of growth factors on AKR-2B  
20 cells--Figure 2a shows the effect of heparin on TGF-alpha and purified KAF; Figure 2b shows the effect of heparin on the mitogenic activity of acidic and basic FGF.

Figure 3 shows the effect of various growth factors on thymidine incorporation by MK-2 cells.

25 Figure 4 shows the results of an assay to determine candidate inhibitors of KAF activity.

Figure 5 shows a plot of growth of keratinocytes starting from a  $10^4$  cells/cm<sup>2</sup> density in the presence and absence of heparin.

30 Figure 6 shows the effect of heparin on cell count under the conditions of Figure 5.

Figure 7 shows the effect of KAF fractions eluted from heparin-agarose on the growth of human keratinocytes.

35 Figure 8 compares the effect of KAF-containing fractions on the DNA uptake of neonatal foreskin

**SUBSTITUTE SHEET**



-7-

fibroblast cells, AKR-2B cells, and murine NR-6 cells;  
Figure 8a shows its effect on normal human fibroblasts;  
Figure 8b shows the effect of KAF on AKF-2B cells; and  
Figure 8c shows its effect on EGF-receptorless mouse NR-6  
5 cells.

Figure 9 shows the elution pattern of KAF activity from an affinity column and an assessment of proteins in the eluate.

Figure 10 shows elution patterns from various  
10 steps in the purification of KAF and results from electrophoresis indicating its purity.

Figure 11 shows the N-terminal amino acid sequences of the two forms of KAF protein obtained from keratinocyte conditioned media in comparison to the  
15 N-terminal sequences of amphiregulin.

Figure 12 shows the nucleotide sequence of DNA obtained using the PCR reaction from human keratinocyte RNA.

Figure 13 shows the results of Northern blot  
20 analysis from various cell cultures.

Figure 14 shows the effect of KAF and TGF-alpha on clonal growth of human keratinocytes.

Figure 15 shows the effect of KAF and other growth factors on fibroblast growth.

Figure 16 shows a comparison of the activities  
25 of TGF-alpha, EGF and KAF on clonal growth of MK-2 cells.

Figure 17 shows competition of KAF, TGF-alpha and EGF for <sup>125</sup>I-EGF binding and the effect of heparin thereon.

30

#### Modes of Carrying Out the Invention

The invention relates to keratinocyte autocrine factor (KAF) which is produced by human keratinocytes and mammary epithelial cells. This protein, while similar to  
35 amphiregulin referenced above, has a number of properties undisclosed in the art which result in methods and

SUBSTITUTE SHEET

-8-

materials useful in diagnosis and therapy. Notable among these are the following:

1. The inhibition of KAF activity by heparin sulfate permits the isolation of effects of KAF activity  
5 in a manner that distinguishes them from those of other growth factors. Thus, assays designed to measure cell growth can be made specific for KAF by running them in the presence and absence of heparin sulfate. The assays can be used to determine suitable substitutes for heparin  
10 inhibition such as other inhibitory sulfated glycosaminoglycans or sugars. The growth stimulating activity exhibited in the absence of heparin (or other specific inhibitor) minus that exhibited in the presence of heparin is attributable to KAF specifically, and not to  
15 other growth factors which would otherwise interfere, such as TGF-alpha. The availability of this specific assay for KAF permits systematic determination of which among candidate substances are capable of stimulating and which inhibiting the effect of KAF, as well as a convenient  
20 assay method for use in following KAF purification. Thus, the assay specific for KAF is also useful in identifying KAF-containing fractions during purification procedures designed to isolate this protein. KAF stimulating and inhibitory factors are useful in therapeutic applications  
25 associated with conditions characterized by excessive or inadequate KAF activity, as further described below.

2. The ability of heparin and other sulfated carbohydrates to bind KAF also provides a convenient tool for isolation and purification of this protein from  
30 natural sources or from recombinant cells in which it is produced. Use of the appropriate sulfated carbohydrates as affinity ligands bound to solid supports permits the use of specific affinity chromatography or batchwise adsorption and elution to isolate KAF.

35 3. Also because KAF binds sulfated heparin and other sulfated carbohydrates, drug delivery systems which

-9-

provide a matrix which specifically binds KAF can be designed to effect slow and controlled delivery of KAF.

4. Inhibitors of KAF are useful in the control of hyperproliferative diseases as outlined further below.

5 All of the compounds found by the invention assay to inhibit KAF mitogenic activity can be used in this way as further described herein. However, it is also known from Figures 5 and 6 that heparin, and presumably alternate sulfated carbohydrates, are capable of inhibiting the growth of keratinocytes regardless of the mechanism thereof. Thus, compounds which merely are shown by the assays carried out in Example 1 below are useful in such treatment protocols.

5. Because KAF is an autocrine factor, it can be used to enhance the growth of clonal cells in culture starting at low cell densities such as those that would be used in preparing artificial skin for grafting. Although amphiregulin has been reported to support the growth of mouse keratinocytes, the disclosures presently in the art report only the stimulation of Balb/c MK-cells--cells which have been shown by the applicant not to produce KAF. Furthermore, KAF fails to stimulate the growth of these cells at clonal density. The ability of KAF to stimulate the growth of human keratinocytes and mammary epithelial cells from clonal densities permits the use of this substance to prepare skin in culture.

6. Also because KAF is an autocrine factor, stimulators and inhibitors of its production can be identified by testing the effect of candidate substances on the production of KAF mRNA and/or protein in human keratinocyte cell cultures.

7. It has also been determined that KAF is significantly more effective in stimulating the growth of keratinocytes than in stimulating the growth of fibroblasts. As fibroblasts are responsible for the scarring observed in wound healing, KAF is a particularly

**SUBSTITUTE SHEET**

-10-

advantageous material for use on surface wounds and abrasions which otherwise involve the formation of large amounts of scar tissue.

The paragraphs below describe the methods and compositions which are useful as a result of these newly disclosed properties of KAF.

#### Specific Assays for KAF Activity

Because of the unique property of KAF associated with its inhibition by heparin sulfate or other sulfated carbohydrates, growth assays can be made specific for KAF. In particular, we have demonstrated that the use of AKR-2B cells in a mitogenic assay can be used for the specific detection of KAF activity, including its application to track the purification of KAF from complex mixtures of growth factors. The mitogenic activity of crude keratinocyte conditioned medium in this assay is only partially inhibited by the addition of heparin sulfate indicating that both heparin-inhibitable and non-heparin-inhibitable growth factors are present in this conditioned medium (Figure 1). When this material is bound to a heparin-acrylamide column and then eluted with a NaCl gradient and samples tested in the AKR-2B cell assay in the presence and absence of heparin sulfate (10 ug/ml), active fractions which are inhibited by heparin are indicative of KAF activity. Other EGF-like factors (TGF-alpha or EGF) do not have this property, as shown in Figure 2a, nor do other heparin-binding growth factors such as aFGF or bFGF (Figure 2b); the activity of aFGF is markedly stimulated by heparin. Figure 3 summarizes analogous results for MK-2 cells which could thus be used in a similar fashion to detect KAF activity and distinguish this activity from that of other growth factors. As seen in Figure 3, heparin also diminishes greatly the growth of MK-2 cells stimulated by KAF.

-11-

Thus, the specific assay for KAF in general depends on using as substrate cells responsive to stimulation by KAF. Such cells include human keratinocytes at clonal densities, AKR-2B cells, MK-2  
5 cells, and the like. Growth is assessed at suitable concentrations of growth factor by measurement of typical indicators of growth, such as labeled thymidine incorporation, colony formation and increased cell number. Matching concentrations are run in the presence of a  
10 suitable inhibitory sulfated carbohydrate such as heparin sulfate. Since this ability is known for heparin sulfate, the assay described in AKR-2B cells described above, for example, can be used to determine other appropriate sulfated GAG or sulfated sugar inhibitors of KAF mitogenic  
15 activity. The results of such an assay are shown in Figure 4.

As shown in Figure 4, when AKR-2B cells are stimulated by KAF in the presence of 500 ng/ml insulin, sulfated compounds such as heparin, heparan, low molecular  
20 weight dextran sulfate (LDS) and high molecular weight dextran sulfate (HDS) are potent inhibitors of KAF activity (panels b and d) but not the EGF activity shown in panels a and c (EGF=2 ng/ml; test compounds at concentrations that are maximally inhibitory for KAF).  
25 Compounds such as chondroitin sulfate B (CSB) and chondroitin sulfate C (CSC) which are also sulfated are not nearly as effective. Nonsulfated low molecular weight dextran (LD) has no effect on KAF activity indicating that the sulfation is essential for KAF inhibition.

30 The following describes an illustrative protocol for the use of target cells with and without addition of heparin sulfate or other sulfated GAG or carbohydrate to assess candidate compounds for their ability to stimulate or enhance KAF activity specifically. Of course, this  
35 assay can be modified by using other cells known to be responsive to KAF, such as MK-2 cells, human keratinocytes,

-12-

and mammary epithelial cells; by using other methods of detection of growth, and by using alternate specific inhibitors of KAF activity. The illustrative steps in such an assay are as follows:

- 5           1. AKR-2B or a subclone derived from these cells (E11A3) are plated in multiwell dishes at a concentration of  $5 \times 10^3$  cells/cm<sup>2</sup> in medium McCoy's 5A supplemented with 5% FBS and grown to confluence over a 5 day period.
- 10           2. The medium in the wells is changed to medium MCDB 402 (Shipley and Ham In Vitro (1981) 17:656-670) without additional supplementation and the cells are incubated for an additional 48 hours.
- 15           3. The medium is changed to fresh medium MCDB 402 supplemented with 500 ng/ml insulin. For the detection of KAF mitogenic activity, samples suspected of containing KAF are added at appropriate concentrations with and without additional supplementation with 10 ug/ml heparin sulfate. Control wells receive 10 ng/ml EGF with  
20 and without 10 ug/ml heparin sulfate. The enhancement of tritiated thymidine incorporation in the wells lacking heparin sulfate over those in which heparin sulfate is present is a measure of KAF activity.
- 25           4. For detection of potential KAF stimulating and inhibiting compounds, KAF as determined above is added at concentrations between 0.01 and 10 nM such that the resultant stimulation is approximately 1/2 maximal to just maximal. EGF and/or other control growth factors (such as bFGF and/or aFGF) are added to control wells at similar  
30 concentrations. Varying concentrations of putative inhibitors are then added and the cultures are incubated at 37°C.
- 35           5. After an additional 22 hours of incubation, 1.0 uCi/ml 3H-deoxythymidine (50-80 Ci/mMol) is added in a small volume and the cultures incubated for 1 hour at 37°C. The relative amount of incorporated label is then

**SUBSTITUTE SHEET**

-13-

determined as described in Shipley, J Tiss Cult (1986) 10:117-123, incorporated herein by reference, or by other common methods.

5 Use of Human Keratinocytes to Detect Agents That Have the Ability to Regulate Endogenous Production of KAF

Human keratinocytes isolated from fetuses, newborn or adult skin and grown in culture, or cell lines derived from these sources may be utilized for  
10 identification of agents that regulate KAF production at the transcriptional, post-transcriptional, translational or post-translational processing steps. The cells can be isolated utilizing a number of techniques including those described in Wille, et al. (J Cell Physiol (1984) 121:31-  
15 44) and grown as described in Shipley et al. (J Cell Physiol (1989) 138:511-518), or other suitable serum-free formulations of medium MCDB 153 such as the commercially available medium KBM (Clonetics Corp., San Diego, CA) for stock culture propagation. KBM is modified MCDB 153  
20 medium containing  $1 \times 10^{-4}$  M ethanolamine,  $1 \times 10^{-4}$  M phosphoethanolamine, and higher amino acid concentrations as described in Pittelkow et al., Mayo Clin Proc (1986) 61:771-777.

For determinations of KAF-production regulating  
25 materials, cells from primary, secondary or tertiary culture of normal keratinocytes or keratinocyte-derived cell lines are removed from the stock culture flasks with trypsin/EDTA, resuspended in medium supplemented with 0.5% FBS, centrifuged and resuspended in medium KGM. KGM is  
30 KBM medium (described above) supplemented with 0.4% bovine pituitary extract (BPE), EGF, insulin and hydrocortisone by the manufacturer. The cells are plated at a suitable density for the particular assay (between  $1 \times 10^3$  and  $5 \times 10^4$  cells/cm<sup>2</sup>) and incubated overnight in a cell  
35 culture incubator. The following morning, the medium is removed and replaced with medium KBM supplemented with

-14-

5  $5 \times 10^{-7}$  M hydrocortisone or the same medium supplemented with hydrocortisone and 5.0 ug/ml insulin. The incubation is continued for a suitable time to allow the cells to achieve a steady state of growth (usually 2-3 days should be sufficient).

Candidate agents to be assessed for their ability to modify the production of KAF are added with fresh medium over a range of concentrations and the production of KAF mRNA and/or protein is measured over  
10 time. Methods for monitoring KAF mRNA levels include but are not limited to: Northern blot, solution hybridization, RNase protection, and/or quantitative polymerase chain reaction techniques. Methods for monitoring KAF protein include but are not limited to:  
15 Western blot, immunoprecipitation, radioimmunoassay, ELISA, AKR-2B cell thymidine incorporation assay,  $^{125}\text{I}$ -EGF binding assay and/or MK-2 cell thymidine incorporation assay techniques.

Thus, by using the production of KAF mRNA or  
20 protein in keratinocytes as a criterion, stimulator and inhibitors of KAF production can be identified.

Use of KAF and/or Agents That Regulate KAF Activity and/or Production in Therapy

25 KAF is an autocrine growth factor for human keratinocytes and, thus, is an important regulator of keratinocyte proliferation and differentiation in vivo. Aberrant production of KAF may be involved in pathological states in human skin and the epithelium of other tissues.  
30 Regulation of KAF production and/or activity can be used therapeutically to treat conditions which are caused or abetted by too much or too little KAF activity or production.

Conditions which would benefit by administration  
35 of KAF or of stimulators of its production and/or activity include: lupus erythematosus; corticosteroid-induced

**SUBSTITUTE SHEET**



-15-

atrophy; pemphigus, pemphigoid; epidermal thinning associated with aging; epidermal ulcerations, including decubitus ulcers, ischemic ulcers, infarctive ulcers, vascular ulcers, and hemoreologic ulcers; androgenetic  
5 alopecia; and alopecia areata.

Conditions which would benefit by administration of an inhibitor of KAF activity and/or production include: psoriasis; pityriasis rubra pilaris; acanthosis nigricans; ichthyosis; exfoliative dermatitis; erythrokeratoderma  
10 variabilis, Darriers disease; as well as squamous cell carcinomas--especially of the skin, lung and urogenital tract; adenocarcinomas--especially of the breast; and basal cell carcinomas of the skin.

In skin disease states characterized by  
15 hypoactivity or hypoproduction of KAF, the application of KAF or agents which cause stimulation of its activity in a suitable cream or other type of salve will be effective in ameliorating the condition. In addition, pharmaceutical agents which can increase the production of endogenous KAF  
20 by keratinocytes and cells derived from keratinocytes in hair follicles will be effective in the treatment of these conditions.

In the conditions characterized by an excess of KAF activity, the application of agents that inhibit the  
25 biological activity of KAF such as heparin sulfate and dextran sulfate or other compounds as described herein, or other KAF inhibitors which can be identified using the assays described above will be effective in treatment of these conditions. Likewise, the treatment of these  
30 conditions with pharmaceutical agents shown to inhibit the endogenous production of KAF by keratinocytes will be effective in ameliorating these conditions.

KAF is useful in the treatment of skin abrasions, burns and other epidermal wounds such as  
35 bedsores and burns. The cell-type specificity of KAF in stimulating keratinocytes at lower concentrations than

-16-

that required for fibroblasts as shown below is crucial for its use as an epidermal healing agent when incorporated into dressings for bandages or applied directly to the surface in a salve or cream.

5           For use in treatment, the KAF is formulated using standard pharmaceutical excipients suitable to its mode of administration. Typically, the administration will be topical, and therefore formulations into ointments, creams, solutions, gels, and lotions are  
10 preferred. Typical formulations for such compositions are found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, latest edition.

          The KAF is formulated to comprise appropriate amounts of the compositions according to the nature of the  
15 excipient and the nature of the lesion or condition being treated. Suitable dosage levels depend on a number of well-known factors, and can be optimized using standard methods known in the art.

## 20   KAF-Delivery Systems

          For the delivery of KAF to any site in the body, and in particular for application of KAF or any derivatives of KAF to the body surface, reversible binding of KAF to immobilized supports and/or immobilized supports  
25 incorporated into bandages is advantageously effected by immobilization of sulfated compounds which bind KAF with high affinity such as heparin sulfate, dextran sulfate or sulfated carbohydrates or other compounds which can be identified by the techniques described herein. When bound  
30 to such immobilized supports the growth factor is in an inactive state and the matrix acts as a continuous source of active KAF as the growth factor is slowly released.

35

-17-

Use of KAF for Propagation of Cells in Vitro

KAF is useful for the propagation of keratinocytes in culture; for the selective growth of keratinocytes from mixed populations of cells (especially  
5 mixed populations containing fibroblasts); for the growth of keratinocytes in vitro for the purpose of autografting and allografting these cells in the treatment of burns or skin lesions using techniques such as those described (Pittelkow et al., Mayo Clin Proc (1986) 61:771-777). The  
10 condition for clonal growth of cells using KAF are set forth in the Examples below.

Use of Heparin Sulfate as an Affinity Support in KAF Purification

15 The examples below illustrate the use of heparin sulfate and other sulfated carbohydrates, such as heparan sulfate and dextran sulfate in the purification of KAF from biological samples. The techniques employed are otherwise standard in the art, including the ligation of  
20 the binding affinity ligand to a solid support and application of chromatographic techniques, both fractionation and batch-wise separations.

Recombinant Production of KAF

25 Provision of a suitable DNA sequence encoding the desired protein KAF permits the production of the protein using recombinant techniques now well known in the art. The coding sequence can be obtained by retrieving a cDNA or genomic sequence from a native source of the  
30 protein or can be prepared synthetically using the accurate amino acid sequence found by careful protein sequencing and/or deducing the amino acid sequence from the nucleotide sequence of the gene. When the coding DNA is prepared synthetically, advantage can be taken of known  
35 codon preferences of the intended host.

-18-

Expression systems containing the requisite control sequences, such as, promoters, and preferably enhancers and termination controls, are readily available and known in the art for a variety of hosts.

5           Thus, the desired proteins can be prepared in both procaryotic and eucaryotic systems, resulting, in the case of many proteins, in a spectrum of processed forms. The most commonly used procaryotic system remains E. coli, although other systems such as B. subtilis and  
10 Pseudomonas could also be used. Suitable control sequences for procaryotic systems include both constitutive and inducible promoters including the lac promoter, the trp promoter, hybrid promoters such as the tac promoter, and the lambda phage P<sub>1</sub> promoter. In  
15 general, foreign proteins may be produced in these hosts either as fusion or mature proteins; when the desired sequences of KAF are produced as mature proteins, the sequence produced may be preceded by a methionine which is not necessarily efficiently removed. Accordingly, the  
20 peptides and proteins claimed herein may be preceded by an N-terminal Met when produced in bacteria. Moreover, constructs may be made wherein the coding sequence for the peptide is preceded by an operable signal peptide which results in the secretion of the protein. When produced in  
25 procaryotic hosts in this manner, the signal sequence is removed upon secretion.

A wide variety of eucaryotic hosts is also now available for production of recombinant foreign proteins. As in bacteria, eucaryotic hosts may be transformed with  
30 expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein. Eucaryotic systems have the additional advantage that they are able to process introns which may occur in the genomic  
35 sequences encoding proteins of higher organisms, such as KAF. Eucaryotic systems also provide a variety of

-19-

processing mechanisms which result in, for example, glycosylation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth.

Commonly used eucaryotic systems include yeast, insect cells, mammalian cells, avian cells, and cells of higher plants. The list is not exhaustive. Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and enhancers. As above, promoters can be either constitutive or inducible. For example, in mammalian systems, the MTII promoter can be induced by the addition of heavy metal ions.

The particulars for the construction of expression systems suitable for desired hosts are well known to those in the art. For recombinant production of the KAF protein, the DNA encoding it is suitably ligated into the expression system of choice, and the system is then transformed into the compatible host which is then cultured and maintained under conditions wherein expression of the included gene takes place. The protein thus produced is recovered from the culture, either by lysing the cells or from the culture medium as appropriate.

## 25 Antibody Production

Antibodies may be prepared to the KAF of the invention using standard immunization protocols. The protein is injected into suitable hosts such as rabbits, mice, rats or sheep usually in the presence of an adjuvant. Immunization with the protein is repeated until high titers of antibodies appear in the serum. The polyclonal serum provides a source of antibodies satisfactory for some applications; however, immortalized cells which secrete monoclonal antibodies immunoreactive with the protein may be prepared using standard techniques from the spleen or peripheral blood lymphocytes of the

-20-

immunized animal. The resulting immortalized cells can be cultured in vitro to obtain a reproducible source of antibody, or may be injected into, for example, mice, and the antibodies harvested from ascites fluid.

5           The following examples are intended to illustrate but not to limit the invention.

#### Example 1

##### Secretion of KAF

10           Keratinocytes were grown in the defined medium KBM supplemented with  $5 \times 10^{-7}$  M hydrocortisone and 5 ug/ml insulin in the absence of EGF at an initial concentration of  $1.0 \times 10^4$  cells/cm<sup>2</sup>. As shown in Figure 5, without the addition of heparin (squares) growth is rapid after an  
15 initial lag phase. However, heparin added at 10 ug/ml in the original culture (circles) results in complete inhibition of proliferation; as does the addition of TGF-beta (triangles) used as a control.

          Cells were cultured at various levels of heparin  
20 in the same manner as described for Figure 5 and growth was measured after 5 days with the results shown in Figure 6. At 1 ug/ml heparin, growth was almost completely inhibited; half maximal growth inhibition occurred at 0.1 ug/ml, and inhibition was dose-dependent  
25 between 0.01 and 100 ug/ml.

#### Example 2

##### Partial Purification of KAF

          Keratinocytes were plated in KGM medium at a  
30 density of  $2.5 \times 10^3$  cells/cm<sup>2</sup> in 100 mm tissue culture dishes. After 48 hours incubation the cells were fed fresh medium and 24 hours later the cells were washed 3 times in a HEPES buffered saline solution ("Solution A," Shipley and Ham, In Vitro (1981) 17:656-670) and  
35 subsequently cultured for 24 hours in KBM medium supplemented with  $5 \times 10^{-7}$  M hydrocortisone (standard

-21-

medium). The medium was then replaced with fresh standard medium.

Keratinocyte conditioned medium was thereafter collected every 24 hours for 4-5 days until the cells  
5 reached 90-100% confluency. Keratinocyte conditioned medium (4.2 L) was frozen at  $-80^{\circ}\text{C}$  and later thawed and pooled for concentration. Concentrate was 43-fold at  $4^{\circ}\text{C}$  using a Millipore Minitan concentrator utilizing 10,000 kd cutoff filters.

10 Concentrated keratinocyte conditioned medium (67.5 ml) was diluted with water to adjust the salt concentration to 0.1 M and manually passed over 0.5 ml of washed heparin-agarose beads (Sigma Chemical Co.). The column was then washed with 6 ml solution A containing  
15 50 ug/ml BSA (hereinafter, solution A + BSA) and heparin-agarose-bound material was eluted from the column with the stepwise application of 1.5 ml volumes of solution A + BSA containing 0.15, 1.0 and 2.0 M NaCl, respectively. The three elution fractions were collected separately,  
20 aliquoted, and frozen at  $-80^{\circ}\text{C}$  for use in experiments. KAF activity was eluted from the column with increased NaCl concentrations.

Figure 7 shows that KAF stimulation of clonal growth of human keratinocytes can be used to assess KAF-  
25 containing fractions. The "control" shown in Figure 7 represents keratinocytes plated in KGM medium for 20 hours and then cultured in KBM medium supplemented with hydrocortisone ( $5 \times 10^{-7}$  M) and insulin (5 ug/ml). Under these conditions, little growth occurred. Similarly  
30 prepared cultures were treated with eluants from the heparin-agarose column at concentrations from 0.3x to 10x the original conditioned medium concentration. Clonal growth was stimulated by both the 1.0 m and 2.0 M eluants and this was inhibited by heparin, also as shown in  
35 Figure 7. No KAF activity eluted in the 0.15 M NaCl fraction. TGF-alpha also stimulated clonal growth in

-22-

these cultures, but this activity was not inhibited by heparin.

KAF from the 1 M or 2 M NaCl eluates as described above stimulated DNA synthesis in cultures of mouse AKR-2B cells cultured in MCDB 402 medium supplemented with 500 ng/ml insulin using the procedure of Shipley, G.D., J Tiss Cult Meth (1986) 10:117-123, incorporated herein by reference, which described the assay for determination of other growth factors.

Stimulation of DNA synthesis in AKR-2B cells by KAF was completely inhibited by the addition of 10 ug/ml heparin sulfate (Figure 8b, see arrow). No other known purified growth factors are inhibited by heparin in this assay or in the other assays shown here.

Thus, these assays when used in the presence and absence of heparin, as described herein, are useful in tracking the purification of KAF. (The same assays are also useful in the discovery of other molecules which have the ability to inhibit KAF as shown herein.) At the same concentrations as capable to stimulate AKR-2B cell growth, KAF was unable to stimulate DNA synthesis in normal human fibroblasts or in EGF-receptorless mouse NR6 cells under similar conditions. bFGF was used as a positive control in these determinations. Figure 8 shows these results.

Figure 8a shows the results obtained for the indicated fractions, normal human fibroblasts; Figure 8b using AKR-2B cells, and Figure 8c using NR6 cells. Only AKR-2B cells are responsive to the KAF-containing 1M and 2M salt fractions. These results led us to use the AKR-2B cell thymidine incorporation assay to purify KAF from keratinocyte conditioned medium.

### Example 3

#### Isolation of Pure KAF

Keratinocytes were plated initially in medium KGM (Clonetics Corporation, San Diego, California) at a

**SUBSTITUTE SHEET**



-23-

density of approximately  $2 \times 10^3$  cells/cm<sup>2</sup>. The keratinocytes were grown in medium KGM for 2 to 3 days until rapidly proliferating cultures were obtained. The cultures were washed thoroughly with solution A and the medium replaced with medium KBM (Clonetics Corporation, San Diego, California) supplemented only with  $5 \times 10^{-7}$  M hydrocortisone (0.25 ml/cm<sup>2</sup>). (Other supplementation such as insulin or EGF may also be used.) The cells were grown for 24 hours and then the medium was collected and discarded. The cell cultures received fresh KBM medium supplemented with hydrocortisone and the cultures were then allowed to grow with medium changes every 48 hours initially and every 24 hours once the cells reached high density. Except for the first medium change which was discarded, all of the conditioned medium from keratinocyte cultures was stored frozen at -20°C until processed as described below.

Frozen keratinocyte conditioned medium was thawed and pooled in 9-18 liter batches and high molecular weight material in the medium was precipitated by adding zinc sulfate to a final concentration of 0.1 M. The high molecular weight precipitate was concentrated by centrifugation. The resulting precipitates were resuspended in 0.5 M EDTA (pH 7.4), suspensions from several centrifuge bottles combined, and the resuspended precipitate was extensively dialyzed against 1% acetic acid utilizing Spectropor dialysis tubing (3,500 M.W. cut-off). The dialyzed material was concentrated to a smaller volume (150-300 ml) by using centrifugal filtration concentration devices (Centricon-10, Amicon). The concentrated material was subsequently lyophilized to dryness and stored at -20°C until use.

The lyophilized material was resuspended in a HEPES buffered saline solution (0.02 M HEPES, 0.1 M NaCl,  $3.3 \times 10^{-6}$  M phenol red, pH 7.0) and the pH was readjusted to approximately 7.0-7.4 with NaOH as required. HEPES

**SUBSTITUTE SHEET**

-24-

buffer as described above but containing no NaCl was then added to the solution to adjust the final salt concentration to approximately 0.1 M. The final volume of resuspended high molecular weight keratinocyte-derived conditioned medium material from 10 liters of conditioned medium was approximately 75-100 ml.

Batches of resuspended conditioned medium material were passed twice over a 1.0 ml column of heparin-acrylamide beads (Sigma Chemical Company, St. Louis, Missouri) at a flow rate of 0.8 ml/min. The heparin-acrylamide column was then washed for 20 minutes with HEPES-saline buffer at a flow rate of 0.5 ml/min. After the wash period, heparin-acrylamide bound material was eluted in a continuous NaCl gradient (0.1-3.0 M NaCl) in 0.02 M HEPES, pH 7.0. The total volume of the gradient elution was 10 ml. The flow rate through the column was 0.5 ml/min. and 0.5 ml fractions were collected.

A small portion of each fraction was diluted in solution A containing 50 ug/ml bovine serum albumin (BSA) as a carrier protein and the diluted material was tested for mitogenic activity in the AKR-2B thymidine incorporation assay described above.

A typical elution profile is shown in figure 9a. The peak of KAF mitogenic activity eluted at approximately 1.75 M NaCl.

The peak fractions from 5 separate heparin-acrylamide purification runs performed essentially as described for figure 9a, representing 65.5 liters of keratinocyte conditioned medium, were pooled. The volume was reduced using filtration with Centricon-10 (Amicon) and the final volume was adjusted to 2.5 ml with 0.02 M HEPES (pH 7.0). The pooled material was tested in the AKR-2B cell thymidine incorporation assay with and without the addition of 10 ug/ml heparin sulfate as shown in figure 9b. As previously demonstrated (Figure 8b), KAF purified by heparin-affinity chromatography is a potent

-25-

simulator of DNA synthesis in mouse AKR-2B cells and this mitogenic activity is blocked by the addition of 10 ug/ml heparin sulfate to the culture medium.

The amount of KAF mitogenic activity is  
5 quantified by comparison to an external standard. One unit of KAF activity is defined as the amount of material required to achieve 1/2 of the maximal mitogenic stimulation which can be induced by the addition of 10 ng/ml EGF to AKR-2B cells in the presence of 500 ng/ml  
10 insulin (indicated in Figure 9b by the arrow). Based on this estimation, the amount of KAF activity that was obtained from 65.5 liters of keratinocyte conditioned medium was 25,939 units.

Pooled KAF activity isolated by heparin-  
15 acrylamide chromatography (300 units) was analyzed by SDS-PAGE under nonreducing conditions followed by silver staining as shown in Figure 9c. This analysis demonstrates that numerous proteins are present in the heparin-acrylamide purified material.

20 KAF was further purified by ion exchange chromatography on a mono-S cation exchange column (Pharmacia). Heparin-acrylamide purified KAF was applied to a mono-S exchange column in 0.02 M HEPES buffer containing 0.15 M NaCl (pH 7.0). The column was eluted in  
25 the same buffer with an increasing concentration gradient of NaCl as shown in Figure 10a. The flow rate was 0.5 ml/min. and 0.5 ml fractions were collected. A portion of each fraction was diluted in saline solution A+BSA and tested in the AKR-2B cell thymidine  
30 incorporation assay as described above, either in the presence or absence of 10 ug/ml heparin sulfate. The results of this assay are shown in figure 10a. The peak of KAF mitogenic activity eluted from the mono-S column at approximately 0.8 M NaCl.

35 Approximately 16,500 units of KAF activity were recovered from fractions 10-12. Equal volumes from

-26-

fractions 9-14 were analyzed by SDS-PAGE and subsequent silver staining. The volume loaded from fraction 11 contained 300 units of KAF mitogenic activity. Analysis of this SDS-PAGE under nonreducing conditions (Figure 10b) indicated that a protein which migrated with an approximate molecular weight of 19,700 daltons correlated with KAF mitogenic activity.

KAF purified by mono-S cation exchange chromatography was further purified by reverse-phase chromatography using a C-8 column (Pharmacia). Peak fractions 10, 11 and 12 from the cation exchange column shown in figure 10a were pooled and diluted to a final volume of 3.0 ml with 0.1% TFA in water. The sample was applied to a C-8 column, and the column subsequently washed with 10 ml of 0.1% TFA at a flow rate of 0.5 ml/min. After washing, a gradient of acetonitrile in 0.1% TFA and water was applied to the column at a flow rate of 0.5 ml/min. as shown in Figure 10c. Fractions (0.5 ml) were collected. A small portion of each fraction was diluted in solution A+BSA and tested for mitogenic activity in the AKR-2B cell thymidine incorporation assay as described above. The results of the thymidine incorporation assay are shown in figure 10c. Heparin-inhibitable KAF mitogenic activity eluted from the C-8 column at approximately 18% acetonitrile. Equal volumes of fractions 11 through 17 were subjected to SDS-PAGE followed by silver staining (Figure 10d). In addition, the same volumes of fractions 12 and 13 were analyzed by SDS-PAGE after reduction with dithiothreitol (Figure 10d). Analysis of the data shown in Figure 10d, demonstrated that a protein which migrates with an approximate molecular weight of 19,700 daltons under nonreducing conditions and 18,500 daltons under reducing conditions correlates with KAF biological activity.

Reversed phase purified KAF activity was further purified by C-8 reversed phase chromatography utilizing a

**SUBSTITUTE SHEET**

-27-

shallow acetonitrile gradient (Figure 10e). KAF activity from fraction 13 of figure 10c was lyophilized and resuspended in 0.1% TFA. The KAF preparation was applied to a C-8 reversed phase column and the column was eluted  
5 with a shallow gradient of acetonitrile in 0.1% TFA and water (0-15% acetonitrile in 7.5 min., 0.5 ml/min; followed by 15-26.5% acetonitrile in 94 minutes, 0.25 ml/min.). Fractions (0.25 ml) were collected every minute. A small portion from each fraction was diluted in  
10 solution A+BSA and tested in the AKR-2B cell thymidine incorporation assay as described above. The results are shown in Figure 10e. Equal volumes of fractions 19-26 were subjected to SDS-PAGE and silver staining as previously described. The results are shown in  
15 figure 10f.

The results indicated that a protein which migrates in SDS-PAGE under reducing conditions with an apparent molecular weight of approximately 18,500 daltons is responsible for KAF activity. The streaking in the  
20 SDS-PAGE analysis at molecular weights slightly higher than 18,500 could be due to differential glycosylation of the KAF protein. Likewise, the protein band apparent in the peak fractions which migrates in SDS-PAGE at approximately 14,000 daltons could indicate a KAF species  
25 with less glycosylation.

#### Example 4

##### Protein Microsequencing of KAF

Fractions 21 through 23 from the column  
30 chromatography shown in figure 10e were combined and lyophilized. The sample was resuspended in 0.1% TFA in water and aliquoted. A portion of the material was sequenced by automated Edman degradation and a portion was tested for biological activity in the AKR-2B cell  
35 thymidine incorporation assay. Analysis of the data obtained from protein microsequencing and from the AKR-2B

-28-

thymidine incorporation assay indicated that 1 unit of KAF activity in the AKR-2B cell thymidine incorporation assay was equivalent to 0.14 picomoles of KAF peptide.

Protein microsequencing of the first twenty residues of KAF revealed that the KAF preparation contained two peptides, KAF-1 and KAF-2. Analysis of the data and comparison of the microsequence of KAF peptides to known protein sequences revealed a high degree of homology to a polypeptide growth factor termed amphiregulin (AR), a member of the EGF superfamily which includes epidermal growth factor (EGF) and transforming growth factor type-alpha (TGF-alpha) (see Background section). Both KAF and AR have forms that are truncated at the amino terminus by six amino acids (Figure 11). The data suggest that AR and KAF are highly related if not identical proteins.

#### Example 5

##### Molecular Cloning of a KAF cDNA

A cDNA was isolated from keratinocyte mRNA using oligonucleotide primers coding for 5' and 3' regions of AR (Plowman et al., Mol Cell Biol (1990) 10:1969-1981) as shown in figure 12. Human keratinocytes were grown in the same conditions utilized to isolate KAF protein (medium KBM supplemented with hydrocortisone). Poly-A+ RNA was isolated as previously described (Sternfeld et al., J Cell Physiol (1988) 136:297-304; Schwab et al., Nature (1984) 303:497-501). cDNA was synthesized from poly A+ RNA using reverse transcriptase and oligo-dT primers. The cDNA was amplified using the polymerase chain reaction (PCR) technique and the PCR-derived product was subsequently cloned into pTZ19U for synthesis of antisense cRNA probes for Northern blot analysis, and in vectors M13-19 and M13-18 for sequencing. The PCR amplified product was approximately 900 basepairs (bp) long which is in agreement with the predicted length of an AR cDNA

-29-

amplified with these primers (888 bp). Subsequent restriction endonuclease and DNA sequence analysis (Figure 12) revealed that the PCR product obtained coded for AR.

5 Northern blot analysis of poly A+ RNA isolated from human keratinocytes cultured from several different individuals revealed a highly abundant 1.7 kilobase RNA in these cells which hybridizes to the antisense probe synthesized from pTZ19-AR1 (Figure 13, lanes C-I). These  
10 results demonstrate that cultured human keratinocytes contain abundant mRNA coding for AR and support the hypothesis that AR and KAF are very similar if not identical molecules. Neither mRNA isolated from cultured normal human fibroblasts (lane A) nor from cultured normal  
15 human melanocytes (lane B) grown in serum-free medium exhibited the levels of KAF/AR gene expression seen in the mRNA isolated from keratinocyte cultures. This was true of the melanocyte cultures even though they were treated continuously with the phorbol ester, PMA, an agent known  
20 to induce the expression of the AR gene in some cultured human mammary carcinoma cells (Plowman et al., Mol Cell Biol (1990) 10:1969-1981).

In addition to the high levels of expression in keratinocyte cultures, the results in figure 13, lane J  
25 demonstrate for the first time that normal human mammary epithelial cells grown in a serum-free medium (Hammond et al., Proc Natl Acad Sci USA (1984) 81:5435-5439) have high levels of mRNA coding for KAF/AR. This indicates that KAF/AR may be an autocrine growth factor for normal  
30 mammary epithelial cells as well as for keratinocytes and that the culture system used for these studies is useful for the identification of pharmaceutical agents that can regulate the expression of the KAF/AR gene in normal human mammary epithelial cells.

35 Unlike the normal mammary epithelial cells, mRNA isolated from a continuous mammary epithelial cell line

**SUBSTITUTE SHEET**

-30-

(HBL100) did not contain high levels of KAF/AR mRNA (lane K), nor did two mammary tumor cell lines grown in culture in the absence of PMA (HS578T-lane L; BT474-lane M).

5 In addition to these results, other studies have shown that KAF/AR mRNA levels in normal keratinocytes are not elevated by PMA treatment, and that in comparison to normal human keratinocytes, the mouse MK-2 cell line does not contain detectable levels of KAF/AR mRNA.

10

#### Example 6

##### Stimulation of Keratinocyte Clonal Growth by KAF

Purified KAF stimulated the clonal growth of normal human keratinocytes. Keratinocytes were plated at  
15 clonal densities as described above and grown in medium KBM supplemented with hydrocortisone, insulin and the indicated concentration of KAF or TGF-alpha with or without the addition of 30 ug/ml heparin sulfate as indicated in Figure 14.

20 Purified KAF stimulates the clonal growth of these cells at low concentrations and the activity is inhibited by the addition of heparin sulfate at 30 ug/ml (+HEP) to the culture medium. At similar concentrations, TGF-alpha also stimulated keratinocyte clonal growth, but  
25 this activity was not inhibited by heparin.

#### Example 7

##### Differential Activity for Keratinocytes and Fibroblasts

30 As set forth above, partially purified KAF (Figure 8b) or purified (Figure 2a) stimulated DNA synthesis in the AKR-2B cell thymidine incorporation assay and the mitogenic activity of KAF was nearly identical to the activity of TGF-alpha. The ability of KAF to  
35 stimulate DNA synthesis in AKR-2B cells (Figure 2a) correlates with the ability of KAF to stimulate the growth

**SUBSTITUTE SHEET**



-31-

of human keratinocytes (Figure 14). However, when KAF was tested for the ability to stimulate DNA synthesis in human dermal fibroblasts, the concentration of KAF that was required to obtain a response was 30-50 fold higher than the effective concentration of TGF-alpha (Figure 15a). Other heparin-binding growth factors (acidic and basic fibroblast growth factor, aFGF and bFGF) are also effective in stimulating DNA synthesis in human dermal fibroblasts (Figure 15b), however, like TGF-alpha, the effective dose for these factors is significantly lower than the concentrations of KAF required to obtain a response in these cells.

The effective concentration of bFGF and aFGF for keratinocyte growth is similar to the effective concentration required to stimulate dermal fibroblasts (Shipley et al., J Cell Physiol (1989) 138:511-518). Thus, of factors known to effect the growth of both keratinocyte and fibroblast cell types, only KAF has a differential effect. In pharmaceutical preparations of growth factors, KAF would be an effective epidermal healing agent that would be less likely to stimulate the proliferation of fibroblasts in the underlying dermis causing scar formation.

25

#### Example 8

##### Differences Between Human

##### Keratinocytes and Balb/c MK Cells

KAF stimulates DNA synthesis in mouse Balb/c MK keratinocyte cell line at high density but not at clonal density. The mouse keratinocyte-derived cell line, MK-2, has been used widely as a model of normal keratinocyte physiology. However, MK-2 cells are completely dependent on the presence of exogenously added EGF/TGF-alpha for proliferation at both low and high density, unlike human keratinocytes. Moreover, these cells do not synthesize KAF as do normal human keratinocytes. Nevertheless, KAF

-32-

can stimulate DNA synthesis in high density cultures of MK cells and the effect of KAF is blocked by the addition of heparin sulfate as set forth above.

5 The Balb/c MK-2 mouse keratinocyte cell line was  
obtained from Dr. Bernard Weissman. These cells were  
routinely grown in medium KBM supplemented with 10 ug/ml  
Gentamicin sulfate, 5 ug/ml insulin, 10 ng/ml EGF and 0.5%  
FBS. This medium is referred to in the text as "MK  
medium." MK-2 cells were plated in 24 well tissue culture  
10 plates at a density of  $3 \times 10^4$  cells/cm<sup>2</sup> in MK medium.  
After 72 hours of culture, each well was washed two times  
with solution A and 0.1 ml of MK medium without EGF  
supplementation was added to each well. The cells were  
cultured for an additional 24 hours and then the medium  
15 was replaced with MK medium without EGF. Growth factors  
were then added to the wells at the concentrations of  
0.01-1 nM. [<sup>3</sup>H]thymidine (8 uCi/ml) was added to each  
well and the cells were cultured for 24 hours. After this  
culture period, incorporation of [<sup>3</sup>H]thymidine in each  
20 experimental well was determined as described for AKR-2B  
cells above (Shipley, 1986), and enhanced incorporation  
was shown (Figure 3).

Although purified KAF can replace EGF or TGF-  
alpha in stimulating DNA synthesis in MK-2 cells at high  
25 density, clonal growth of these cells is only supported by  
EGF or TGF-alpha and not by KAF (Figure 16). Clonal  
growth of MK-2 cells was carried out utilizing a protocol  
similar to that described for human keratinocytes.  
Briefly, MK-2 cells were trypsinized from stock flasks,  
30 pelleted, resuspended in MK medium, and plated at 275  
cells/well in 24 well plates. After 24 hours of culture  
each well was washed 2 times with solution A and 0.5 ml of  
MK medium without EGF was added to each well.  
Experimental factors were added to corresponding wells, at  
35 the concentrations shown in Figure 16. After 10 days  
incubation, the colonies which developed were fixed in 10%

**SUBSTITUTE SHEET**

-33-

formalin and stained with crystal violet for photography. As seen from these results, colonies appeared when TGF-alpha was added at 0.1-1 nM or when EGF was added from 0.03-1 nM; however, no colonies were formed in plates  
5 containing KAF in this range.

The ability of purified KAF to stimulate the formation of colonies in neonatal human keratinocytes was shown to be positive (Figure 14) while KAF was inactive with a corresponding assay using BALB/c-MK cells.

10

#### Example 9

##### Relationship to EGF

The possibility that KAF and EGF bind to the same receptor on AKR-2B cells was investigated as follows.  
15 The cells were grown as described for thymidine incorporation assays except that at the last medium change the cells received binding buffer (medium MCDB 402 buffered with 20 mM HEPES, pH 7.4, supplemented with 1.0 mg/ml BSA). The ability of KAF, TGF-alpha and EGF to  
20 compete with 50 pM  $^{125}$ I-EGF binding was determined at 4°C. 100% competition was determined by adding an excess of unlabeled EGF (>100 nM). As shown in figure 17a and 17b, KAF as well as TGF-alpha and EGF competed for  $^{125}$ I-EGF binding to AKR-2B cells.

25 The ability of KAF to compete for binding was blocked by the addition of 10 ug/ml heparin sulfate to the binding medium (Figure 17b), whereas binding competition by TGF-alpha (Figure 17b) or EGF (not shown) was not  
30 changed by the addition of heparin. Thus, the ability of heparin sulfate and other sulfated compounds which inhibit KAF mitogenic activity may do so by blocking the ability of KAF to bind to its cell surface binding sites.

35

**SUBSTITUTE SHEET**

-34-

Claims

1. A method to purify keratinocyte autocrine  
5 factor (KAF) which method comprises contacting a sample  
containing the KAF to be purified with a sulfated  
carbohydrate immobilized on a solid-phase support under  
conditions wherein said KAF is adsorbed by the sulfated  
carbohydrate immobilized on the support, and  
10 eluting the adsorbed KAF from the solid support.

2. The method of claim 1 wherein the sulfated  
carbohydrate is heparin sulfate.

15 3. The method of claim 1 wherein the KAF is  
eluted from the solid support in a protocol which  
generates a multiplicity of elution fractions, only a  
portion of which contains KAF.

20 4. The method of claim 3 wherein the elution  
fractions containing KAF are identified by assessing the  
ability of each fraction to enhance labeled thymidine  
incorporation in serum-free AKR-2B cell cultures, wherein  
said ability is inhibited by heparin.

25 5. A method to inhibit the mitogenic effect of  
KAF on responsive cells in culture, which method comprises  
adding to the culture an amount of sulfated carbohydrate  
or other compound effective to inhibit said mitogenic  
30 effect.

6. The method of claim 5 wherein the sulfated  
carbohydrate is heparin sulfate heparan sulfate, or  
dextran sulfate.

35

SUBSTITUTE SHEET

-35-

7. A method to decrease the mitogenic effect of KAF in a subject which method comprises administering to said subject an amount of sulfated carbohydrate or other compound effective to decrease said mitogenic effect.

5

8. The method of claim 7 wherein the sulfated carbohydrate is heparin sulfate, heparan sulfate or dextran sulfate.

10

9. A method to assess chromatographic fractions for the presence or absence of KAF which method comprises testing the ability of said fractions to stimulate the growth of cells responsive to KAF wherein said ability is inhibited by compounds determined to inhibit KAF.

15

10. A method to determine the ability or inability of a candidate substance to inhibit or stimulate KAF activity, which method comprises assessing the KAF-specific mitogenesis of KAF-responsive cells in the presence of added KAF and in the presence and absence of said candidate substance and comparing the growth of said cells wherein an enhancement in the growth indicates a stimulating effect of said substance and a decreased growth indicates an inhibiting effect.

25

11. A method to assess the ability of a candidate substance to inhibit or stimulate KAF production by KAF-producing cells, which method comprises culturing normal human keratinocytes, immortalized keratinocytes, normal mammary epithelial cells or cell lines in the presence and absence of said candidate substance and comparing the quantity of KAF-mRNA and/or KAF protein produced in said cells, wherein an enhancement of KAF mRNA and/or protein in the presence of said substance indicates a stimulating effect of said substance and a decreased amount of said KAF, mRNA and/or protein in said

35

-36-

keratinocytes in the presence of said substance indicates an inhibiting effect of said substance.

12. The method of claim 11 wherein said mRNA is  
5 detected by hybridization to a cRNA or cDNA probe encoding KAF or a portion thereof.

13. A method to prepare KAF which method  
comprises culturing human keratinocytes or human mammary  
10 epithelial cells under conditions wherein KAF is produced, and

recovering KAF from the culture.

14. The method of claim 13 wherein the cells  
15 are immortalized.

15. The method of claim 13 which further  
includes treating the medium from said cells with a  
sulfated carbohydrate capable of binding KAF immobilized  
20 on a solid support under conditions wherein KAF is  
adsorbed by the sulfated carbohydrate immobilized on the  
support and  
eluting the adsorbed KAF from the solid support.

25 16. The method of claim 15 wherein sulfated  
carbohydrate is heparin sulfate.

17. A method to treat surface wounds to effect  
healing and minimize scarring which method comprises  
30 contacting said surface wounds with an effective amount of  
KAF or pharmaceutical composition thereof.

18. A method to grow keratinocytes from low  
density in culture which method comprises adding to said  
35 culture an amount of KAF effective to enhance growth.

**SUBSTITUTE SHEET**

-37-

19. A pharmaceutical composition suitable for the controlled delivery of KAF, which composition comprises KAF as active ingredient in combination with a sulfated carbohydrate capable of binding KAF configured to  
5 release said KAF over time.

20. Keratinocyte autocrine factor (KAF) in purified and isolated form.

10 21. The KAF of claim 20 which has been purified from human keratinocytes or human mammary epithelial cells.

22. An expression system capable of expressing  
15 the gene encoding KAF in a recombinant host cell under conditions favoring said expression, which expression system comprises a DNA sequence encoding said KAF operably linked to control sequences compatible with a recombinant host cell.

20

23. A recombinant host cell, cell line or cell culture wherein said cells contain the expression system of claim 22.

25 24. A method to produce recombinant KAF which method comprises culturing the cells of claim 23 and recovering the KAF produced.

25. Antibodies specifically immunoreactive with  
30 the KAF of claim 21.

26. A method to treat conditions associated with KAF deficiency which method comprises administering to a subject in need of such treatment an effective amount  
35 of KAF or of a stimulator of KAF activity and/or production or a pharmaceutical composition thereof.

-38-

27. A method to treat conditions associated  
with KAF overactivity which method comprises administering  
to a subject in need of such treatment an effective amount  
of an inhibitor of KAF activity and/or production or a  
5 pharmaceutical composition thereof.

10

15

20


25

30

35



1/17

**Fig. 1**

2/17




Fig. 2

3/17




Fig. 3

4117




Fig. 4

5/17




Fig. 5

4/17





Fig. 6

Fig. 7



8/17




Fig. 8



9/17





Fig. 9

10/17



11/17

Fig. 11

	1	2	3	4	5	6	7	8	9	10
KAF-1	Ser	Val	Arg	Val	Glu	Gln	Val	Val	Lys	Pro
KAF-2	.....						Val	Val	Lys	Pro
AR	Ser	Val	Arg	Val	Glu	Gln	Val	Val	Lys	Pro
AR'	.....						Val	Val	Lys	Pro
	11	12	13	14	15	16	17	18	19	20
KAF-1	Pro	Gln	Asn	Lys	Thr	Glu	Ser	Glu	Asn	Thr
KAF-2	Pro	Gln	Xxx	Lys	Thr	Glu	Ser	Glu	Asn	Thr
AR	Pro	Gln	Asp	Lys	Thr	Glu	Ser	Glu	Asn	Thr
AR'	Pro	Gln	Asp	Lys	Thr	Glu	Ser	Glu	Asn	Thr
	21	22	23	24	25	26				
KAF-1	.....									
KAF-2	Ser	Asp	Lys	Pro	Lys	Arg				
AR	Ser	Asp	Lys	Pro	Lys	Arg				
AR'	Ser	Asp	Lys	Pro	Lys	Arg				

\* alignment of the deduced amino acid sequences for KAF-1 and KAF-2 with the reported amino acid sequence of amphiregulin (AR) and the truncated form of amphiregulin (AR') (Shoyab et al., Proc. Natl. Acad. Sci. USA 85:6528-6532, 1988).

12/17

Fig. 12

153

GCACGAATTCCGTGTCCCAGAGACCGAGTTGCCCCAGAGACCGAGACGCCGC  
 195  
 CGCTGCGAAGGACCAATGAGAGCCCCGCTGCTACCGCCGGCGCCGGTGGTGC  
 247  
 TGTCGCTCTTGATACTCGGCTCAGGCCATTATGCTGCTGGATTGGACCTCAATG  
 301  
 ACACCTACTCTGGGAAGCGTGAACCATTTTCTGGGGACCACAGTGCTGATGGAT  
 355  
 TTGAGGTTACCTCAAGAAGTGAGATGTCTTCAGGGAGTGAGATTTCCCCTGTGAG  
 409  
 TGAAATGCCTTCTAGTAGTGAACCGTCCTCGGGAGCCGACTAT.....  
 451

1021

3' AR (antisense) primer- 3' CCTCAGTGACGGTTCAGTATCGGT TCGAACACG 5'

Underline indicates sequences of primers used for PCR reaction. Numbering above the sequence indicates numbering of nucleotides in the cDNA sequence of Plowman et al., Mol. Cell. Biol. 10:1969-1981, 1990. Sequence shown is the sequence derived from the PCR reaction product from human keratinocyte RNA cloned into vector M13 and is identical to the sequence reported by Plowman et al., 1990.

13/17




Fig. 13

14/17




Fig. 14

15/17





Fig. 15

16/17

Fig. 16





17/17




Fig. 17

**THIS PAGE BLANK (USP):**